Compare FDP & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDP | DFTX |
|---|---|---|
| Founded | 1886 | 2019 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | FDP | DFTX |
|---|---|---|
| Price | $40.23 | $16.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $33.00 |
| AVG Volume (30 Days) | 210.4K | ★ 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.50 | $4.70 |
| 52 Week High | $41.05 | $18.70 |
| Indicator | FDP | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 50.34 |
| Support Level | $39.26 | $15.62 |
| Resistance Level | $40.44 | $17.80 |
| Average True Range (ATR) | 1.03 | 1.16 |
| MACD | 0.06 | -0.10 |
| Stochastic Oscillator | 73.20 | 39.38 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).